Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newly recognized cutaneous drug eruptions.

Jeffrey P Callen1

  • 1Division of Dermatology, University of Louisville School of Medicine, Louisville, KY 40292, USA. jefca@aol.com

Dermatologic Clinics
|April 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upadacitinib for recalcitrant extraintestinal Crohn disease.

JAAD case reports·2026
Same author

Characterizing superficial epidermolytic ichthyosis in a patient with KRT2 mutation responsive to ustekinumab.

JAAD case reports·2026
Same author

Generalized bullous fixed drug eruption related to intravenous contrast.

Dermatology online journal·2025
Same author

Evolution of Subacute Cutaneous Lupus Erythematosus.

JAMA dermatology·2025
Same author

Lupus miliaris disseminatus faciei: A unique presentation with extrafacial involvement.

Dermatology online journal·2025
Same author

Erythromelalgia and the Association With Paraproteinemias: A Retrospective Case Series.

International journal of dermatology·2025

New drugs can cause rare skin reactions not seen in early testing. Careful observation of these drug-induced cutaneous reactions is key to understanding skin diseases.

Area of Science:

  • Dermatology
  • Pharmacology
  • Drug Development

Background:

  • Numerous novel pharmaceuticals are introduced into the market.
  • Preclinical evaluations may identify some cutaneous reactions, but rare adverse events often emerge during widespread drug use.
  • Distinctive dermatological reactions, such as those associated with epidermal growth factor-receptor inhibitors, require specific attention.

Purpose of the Study:

  • To highlight the importance of post-marketing surveillance for identifying rare cutaneous drug reactions.
  • To emphasize the unique dermatological side effects associated with specific drug classes like EGFR inhibitors.
  • To underscore the role of clinical observation in differentiating drug-induced skin conditions from idiopathic dermatoses.

Main Methods:

Related Experiment Videos

  • Systematic review of post-marketing surveillance data.
  • Analysis of case reports and clinical trial data for novel drugs.
  • Comparative evaluation of cutaneous reactions to EGFR inhibitors versus other drug classes.

    • Main Results:

    • Rare and severe cutaneous adverse events are frequently identified after drug market entry.
    • Epidermal growth factor-receptor inhibitors are associated with a distinct spectrum of skin toxicities.
    • Clinical observation is crucial for accurate diagnosis and management of drug-related dermatologic conditions.

    Conclusions:

    • Post-marketing surveillance is essential for detecting rare adverse drug reactions.
    • Understanding drug-specific cutaneous toxicities aids in patient management.
    • Enhanced clinical vigilance improves the characterization of both drug-induced and naturally occurring skin diseases.